#PACTALS2025 Abstract submission deadline has been extended until March 17 - join us in #Melbourne #Australia this September! Showcasing ALS research and care across the Asia-Pacific and hearing perspectives and updates from global colleagues pactalscongress.com @mndaus-research.bsky.social
We looked at the relationship between fatigue and metabolic rate in #ALS. Fatigue is a complex symptom - more needs to be done to understand how we can best address it. @fredsteyn.bsky.social @ammaralchalabi.bsky.social www.tandfonline.com/doi/full/10....
Persistent high levels of perceived fatigue are not associated with hypermetabolism in patients with amyotrophic lateral sclerosis
Objective: Fatigue is a common symptom in amyotrophic lateral sclerosis (ALS). Little is known about factors that contribute to fatigue, and whether levels of fatigue change throughout disease cour...
tandfonline.com
Really excited this is out! We found polyunsaturated fatty acids (PUFAs) were beneficial in models of C9orf72 FTD/ALS and the greatest benefit occurred when increasing levels specifically within neurons @ukdri.ac.uk @uclqsion.bsky.social @ucl.ac.uk @cziscience.bsky.social rdcu.be/ebbZf
Neuronal polyunsaturated fatty acids are protective in ALS/FTD
Nature Neuroscience - Lipidomics revealed that neurons of patients with ALS/FTD have reduced levels of polyunsaturated fatty acid (PUFA)-containing phospholipids. Increasing neuronal PUFA levels...
rdcu.be
Our study on the safety and tolerability of Trimetazidine in #ALS @braincomms.bsky.social Trimetazidine reduced oxidative stress markers and energy expenditure, warranting a follow up study @rpavaneijk.bsky.social @fredsteyn.bsky.social @ammaralchalabi.bsky.social academic.oup.com/braincomms/a...
An open-label phase 2a study to assess the safety and tolerability of trimetazidine in patients with amyotrophic lateral sclerosis
van Eijk et al. report that oral trimetazidine is safe and well-tolerated in amyotrophic lateral sclerosis (ALS) patients, significantly reducing oxidative
academic.oup.com
MND Australia Research@mndaus-research.bsky.social · 2y agoGood to see this Australian-led study ready for the next phase; Open-label phase 2a study to assess the safety and tolerability of trimetazidine in patients with ALS academic.oup.com/braincomms/a... @rpavaneijk.bsky.social @ngoshyuan.bsky.social @fredsteyn.bsky.social @ammaralchalabi.bsky.social
Some new and interesting work on cell-free DNA in #ALS - insights into biomarker potential link.springer.com/epdf/10.1186...
Evaluation of a biomarker for amyotrophic lateral sclerosis derived from a hypomethylated DNA signature of human motor neurons
link.springer.com
A timely piece that everyone should read. There are many challenges but we have a responsibility to communicate outcomes without the over sensationalisation!
Ruben van Eijk@rpavaneijk.bsky.social · 2y agoNew paper to reflect on the main challenges in phase 2 #ALS #MND trials. Key issues relate too short study durations, reliance on the wrong outcome measures, absence of biomarkers, statistical issues, over-interpretation of 'clinical trends' and miscommunication. academic.oup.com/brain/articl...
New paper to reflect on the main challenges in phase 2 #ALS #MND trials. Key issues relate too short study durations, reliance on the wrong outcome measures, absence of biomarkers, statistical issues, over-interpretation of 'clinical trends' and miscommunication. academic.oup.com/brain/articl...
Rethinking phase 2 trials in amyotrophic lateral sclerosis
There is a long history of ALS therapies being promoted on the basis of Phase 2 data, which then fail to translate into meaningful benefits in Phase 3 tria
academic.oup.com
Decision email received at 00:38 - how long does one hold off from logging on to see the bad news???
LRP4 controls SO MUCH more! And it all seems to do so from the PRESYNAPSE (answering that HUGE open question). LRP4 controls synapse growth, cytoskeletal organization, postsynaptic protein recruitment, AND maturation. Multiple processes for the price of one cell surface protein!
